Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial

BACKGROUND. Triplet chemotherapy has demonstrated manageable toxicities and a favorable response rate. The addition of cetuximab to chemotherapy can increase treatment efficacy. We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Assenat, Eric, Desseigne, Francoise, Thezenas, Simon, Viret, Frédéric, Mineur, Laurent, Kramar, Andrew, Samalin, Emmanuelle, Portales, Fabienne, Bibeau, Frédéric, Crapez-Lopez, Evelyne, Bleuse, Jean Pierre, Ychou, Marc
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2011
Gaiak:
Gastrointestinal Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233290/
https://ncbi.nlm.nih.gov/pubmed/22016477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0141
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak